All things considered, it’s at least as likely to make health outcomes worse as it is to make most people healthier.

Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry.

Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Explore more details here.

The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

Kennedy Jr. made it clear in his first US Senate confirmation hearing that his quest to reduce chronic disease would entail a closer look at the food industry, namely manufacturers of packaged foods.

WASHINGTON (AP) — Robert F. Kennedy Jr.’s anti-vaccine advocacy is outside the mainstream. His previous statements on ...

The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine for adults with moderate-to-severe obstructive sleep apnea and obesity. The approval supports evidence ...

The Food and Drug Administration approved Novo Nordisk’s Ozempic as the first GLP-1 treatment option for people with type 2 ...

The FDA has approved PureTech Health’s ‘space occupying’ device Plenity as a new prescription treatment for obesity, setting it up to rival Novo Nordisk in this lucrative market. Plenity ...

Robert F. Kennedy Jr. will have the second of two confirmation hearings for his Health and Human Services Secretary nomination Thursday.